BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24853546)

  • 1. NDY1/KDM2B functions as a master regulator of polycomb complexes and controls self-renewal of breast cancer stem cells.
    Kottakis F; Foltopoulou P; Sanidas I; Keller P; Wronski A; Dake BT; Ezell SA; Shen Z; Naber SP; Hinds PW; McNiel E; Kuperwasser C; Tsichlis PN
    Cancer Res; 2014 Jul; 74(14):3935-46. PubMed ID: 24853546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.
    Kottakis F; Polytarchou C; Foltopoulou P; Sanidas I; Kampranis SC; Tsichlis PN
    Mol Cell; 2011 Jul; 43(2):285-98. PubMed ID: 21777817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells.
    Tzatsos A; Paskaleva P; Lymperi S; Contino G; Stoykova S; Chen Z; Wong KK; Bardeesy N
    J Biol Chem; 2011 Sep; 286(38):33061-9. PubMed ID: 21757686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
    Tzatsos A; Paskaleva P; Ferrari F; Deshpande V; Stoykova S; Contino G; Wong KK; Lan F; Trojer P; Park PJ; Bardeesy N
    J Clin Invest; 2013 Feb; 123(2):727-39. PubMed ID: 23321669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection.
    Sourvinos G; Morou A; Sanidas I; Codruta I; Ezell SA; Doxaki C; Kampranis SC; Kottakis F; Tsichlis PN
    PLoS Pathog; 2014 May; 10(5):e1004136. PubMed ID: 24830456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus.
    Tzatsos A; Pfau R; Kampranis SC; Tsichlis PN
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2641-6. PubMed ID: 19202064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KDM2B is involved in the epigenetic regulation of TGF-β-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
    Wanna-Udom S; Terashima M; Suphakhong K; Ishimura A; Takino T; Suzuki T
    J Biol Chem; 2021; 296():100213. PubMed ID: 33779563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM2B links the Polycomb Repressive Complex 1 (PRC1) to recognition of CpG islands.
    Farcas AM; Blackledge NP; Sudbery I; Long HK; McGouran JF; Rose NR; Lee S; Sims D; Cerase A; Sheahan TW; Koseki H; Brockdorff N; Ponting CP; Kessler BM; Klose RJ
    Elife; 2012 Dec; 1():e00205. PubMed ID: 23256043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FBXL10/KDM2B scaffolding protein associates with novel polycomb repressive complex-1 to regulate adipogenesis.
    Inagaki T; Iwasaki S; Matsumura Y; Kawamura T; Tanaka T; Abe Y; Yamasaki A; Tsurutani Y; Yoshida A; Chikaoka Y; Nakamura K; Magoori K; Nakaki R; Osborne TF; Fukami K; Aburatani H; Kodama T; Sakai J
    J Biol Chem; 2015 Feb; 290(7):4163-77. PubMed ID: 25533466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation.
    Blackledge NP; Farcas AM; Kondo T; King HW; McGouran JF; Hanssen LLP; Ito S; Cooper S; Kondo K; Koseki Y; Ishikura T; Long HK; Sheahan TW; Brockdorff N; Kessler BM; Koseki H; Klose RJ
    Cell; 2014 Jun; 157(6):1445-1459. PubMed ID: 24856970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1.1 and in concert with MYC and ATF4.
    Chavdoula E; Anastas V; La Ferlita A; Aldana J; Carota G; Spampinato M; Soysal B; Cosentini I; Parashar S; Sircar A; Nigita G; Sehgal L; Freitas MA; Tsichlis PN
    Metabolism; 2024 Jan; 150():155719. PubMed ID: 37935302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
    Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
    PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
    Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
    Zacharopoulou N; Tsapara A; Kallergi G; Schmid E; Tsichlis PN; Kampranis SC; Stournaras C
    Biochim Biophys Acta Mol Cell Res; 2018 Apr; 1865(4):587-597. PubMed ID: 29408056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kdm2b maintains murine embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes.
    He J; Shen L; Wan M; Taranova O; Wu H; Zhang Y
    Nat Cell Biol; 2013 Apr; 15(4):373-84. PubMed ID: 23502314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
    Staberg M; Rasmussen RD; Michaelsen SR; Pedersen H; Jensen KE; Villingshøj M; Skjoth-Rasmussen J; Brennum J; Vitting-Seerup K; Poulsen HS; Hamerlik P
    Mol Oncol; 2018 Mar; 12(3):406-420. PubMed ID: 29360266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
    Kuang Y; Xu H; Lu F; Meng J; Yi Y; Yang H; Hou H; Wei H; Su S
    Cancer Sci; 2021 Jan; 112(1):231-242. PubMed ID: 33091189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation.
    Han XR; Zha Z; Yuan HX; Feng X; Xia YK; Lei QY; Guan KL; Xiong Y
    Oncogene; 2016 Aug; 35(32):4179-90. PubMed ID: 26725323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of histone demethylase KDM2A inhibited cell proliferation of stem cells from apical papilla by de-repression of p15INK4B and p27Kip1.
    Gao R; Dong R; Du J; Ma P; Wang S; Fan Z
    Mol Cell Biochem; 2013 Jul; 379(1-2):115-22. PubMed ID: 23559091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.